<DOC>
	<DOCNO>NCT01538654</DOCNO>
	<brief_summary>The purpose esperience : 1. verify safety protein spar modify fast ( PSMF ) enteral route ( EMF ) perform cycle ten days/months six month 2. compare EMF oral PSMF clinically ( appetite control , fat freemass mantainance , polmonary function test metabolic pattern ) 3. verify weight mantainance 6 month treatment suspension</brief_summary>
	<brief_title>Enteroprotein Modified Fast ( EMF )</brief_title>
	<detailed_description>Rationale A ) primary endpoint 1. verify safety protein spar modify fast enteral route ( EMF ) cycle ten days/months repeat six month , 2 . To compare EMF oral PSMF clinically ( appetite control , polmonary function test metabolic pattern ) metabolic parameter ( hypertension , glucose intolerance , dyslipidaemia ) maintain body composition ( particularly fat free mass muscular strength ) 15 patient disease-causing obesity respond medical treatment and/or cognitive/behavioural therapy , candidate invasive treatment gastric balloon surgery intend undergo compare 15 undergoing regimen without naso-gastric tube . To verify effect treatment regard enteral-hormonal structure acute phase ( select sub-group ) undergoing treatment . B ) Secondary endpoint : 1 . To verify percentage patient maintain weight reach 6 month stop treatment naso-gastric tube associate high-calorie normal-protein diet . 2 . Verify clinical safety EN patient .</detailed_description>
	<criteria>gender , outpatient age 16 75 BMI 30 45 Kg/m2 restrict diet since least 3 month obesity relate comorbidities ( type 2 diabetes mild moderate OSAS orthopedic disease ( coxarthrosis , gonarthrosis ) hypertension non alcoholic hepatic steatosis accept enrol study ( sign inform consent ) Presence gastrointestinal disease Presence cancer Patients treat gastrolesive anticoagulant drug Hepatic failure , renal failure multiorgan failure ( cut ) Contraindications enteral nutrition , Mechanical bowel complete , partial chronic obstruction Severe mesenteric ischemia cause hypovolemia Digiunal ileal fistula high output ( 400 mL/die ) Severe modification intestinal function cause enteropathy insufficient absorbent surface , point normal nutritional state maintain Type 1 diabetes Type 2 diabetes treat oral injected drug may cause hypoglycemia ANBN : anorexia bulimia nervosa , evaluation symptom specific test Patients major psychiatric disorder cooperative , alcohol drug addiction disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>obesity</keyword>
	<keyword>PSMF ( protein spar modify fast )</keyword>
	<keyword>Enteral nutrition</keyword>
	<keyword>Tube feeding</keyword>
	<keyword>VLCD ( low calorie diet )</keyword>
	<keyword>Pulmonary function test</keyword>
	<keyword>body composition</keyword>
	<keyword>FFM ( fat free mass )</keyword>
	<keyword>Body fat</keyword>
	<keyword>Handgripstregth</keyword>
</DOC>